The Role of Fat-Free Mass in Weight-Related Complications: A Rapid Review and Meta-Analysis.

Obes RevJul 21, 2026 (epub)
Clinical ResearchEndocrinologyGastroenterologyCardiologyOpen access

Tadesse Asmamaw Dejenie, Paul P Fahey, Haider Mannan et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis reviewed 32 studies involving 138,935 adults with overweight or obesity to assess the relationship between fat-free mass (FFM) metrics and weight-related metabolic complications. It found that low FFM metrics significantly increased the risk of type 2 diabetes (RR=1.46), metabolic syndrome (OR=4.48), cardiovascular disease (RR=2.03), and non-alcoholic fatty liver disease (RR=2.24).

Key findings

  • Low FFM metrics were associated with a 46% increased risk of type 2 diabetes (RR=1.46).
  • The odds of metabolic syndrome were 4.48 times higher with low FFM metrics (OR=4.48).
  • Low FFM metrics doubled the risk of cardiovascular disease (RR=2.03).
  • There was a 2.24-fold increase in the risk of non-alcoholic fatty liver disease (RR=2.24).

Why it matters

Understanding the role of fat-free mass in metabolic complications can help clinicians identify at-risk patients and tailor interventions to improve metabolic health in individuals with overweight or obesity.

Source

PubMed · PMID 42478608Free full text on PubMed Central

Published in Obes Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.